The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NTRK1-3 point mutations in non-small cell lung cancer: Molecular profiling.
 
Yun Soo Park
No Relationships to Disclose
 
Anna Rasokat
No Relationships to Disclose
 
Nele Wagener
No Relationships to Disclose
 
Damla Türkmen
No Relationships to Disclose
 
Diana Schinol
No Relationships to Disclose
 
Felix John
No Relationships to Disclose
 
Lea Ruge
No Relationships to Disclose
 
Malte Verheyen
No Relationships to Disclose
 
Heather Scharpenseel
No Relationships to Disclose
 
Sebastian Michels
No Relationships to Disclose
 
Richard Riedel
No Relationships to Disclose
 
Rieke Fischer
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Janssen
 
Anna Kron
No Relationships to Disclose
 
Achim Rothe
No Relationships to Disclose
 
Jan-Phillip Weber
Honoraria - AstraZeneca; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Lilly; MSD Oncology
Consulting or Advisory Role - Merck
Research Funding - Novartis; OnQ
Travel, Accommodations, Expenses - Daiichi Sankyo/Lilly; Johnson & Johnson/Janssen
 
Reinhard Büttner
No Relationships to Disclose
 
Sabine Merkelbach-Bruse
No Relationships to Disclose
 
Udo Siebolts
No Relationships to Disclose
 
Juergen Wolf
Honoraria - Abbvie; Amgen; Amgen Astellas BioPharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; DISCO Pharmaceuticals; Ellipses Pharma; Genmab; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Roche; Seagen; Takeda; Turning Point Therapeutics; Zuelling Pharma
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi
 
Matthias Scheffler
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Siemens Healthineers; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Janssen Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Siemens Healthineers; Takeda
Research Funding - Amgen (Inst); BMS GmbH & Co. KG (Inst); Dracen (Inst); Janssen (Inst); Novartis (Inst); Siemens Healthineers (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Janssen; Pfizer